These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 17636564)

  • 1. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T; Fossati G; Nesbitt A
    BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.
    Ueda N; Tsukamoto H; Mitoma H; Ayano M; Tanaka A; Ohta S; Inoue Y; Arinobu Y; Niiro H; Akashi K; Horiuchi T
    Inflamm Bowel Dis; 2013 May; 19(6):1224-31. PubMed ID: 23619715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.
    Vos AC; Wildenberg ME; Duijvestein M; Verhaar AP; van den Brink GR; Hommes DW
    Gastroenterology; 2011 Jan; 140(1):221-30. PubMed ID: 20955706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
    Pasut G
    BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
    Chang JT; Lichtenstein GR
    Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
    Palframan R; Airey M; Moore A; Vugler A; Nesbitt A
    J Immunol Methods; 2009 Aug; 348(1-2):36-41. PubMed ID: 19567252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
    Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
    Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS; Nelson M; Dolder CR
    Ann Pharmacother; 2010 Feb; 44(2):333-42. PubMed ID: 20118143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of certolizumab and its potential in the treatment of psoriatic arthritis.
    Chimenti MS; Saraceno R; Chiricozzi A; Giunta A; Chimenti S; Perricone R
    Drug Des Devel Ther; 2013; 7():339-48. PubMed ID: 23620660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease.
    Sandborn WJ
    Curr Gastroenterol Rep; 2003 Dec; 5(6):501-5. PubMed ID: 14602060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
    Molnár T
    Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept.
    Shen C; Assche GV; Colpaert S; Maerten P; Geboes K; Rutgeerts P; Ceuppens JL
    Aliment Pharmacol Ther; 2005 Feb; 21(3):251-8. PubMed ID: 15691299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases.
    Tilg H; Moschen A; Kaser A
    Expert Opin Biol Ther; 2007 Jul; 7(7):1051-9. PubMed ID: 17665993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.